CoChat

GD2‐targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma

Gholamin, Sharareh, Mirzaei, Hamed, Razavi, Seyed‐Mostafa, Hassanian, Seyed Mahdi, Saadatpour, Leila, Masoudifar, Aria, ShahidSales, Soodabeh, Avan, Amir · 2018 · Journal of Cellular Physiology
Cited by 105

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Neuroblastoma (NB) with various clinical presentation is a known childhood malignancy. Despite significant progress in treatment of NB afflicted patients, high risk disease is usually associated with poor outcome, resulting in long‐term survival of less that 50%. Known as a disease most commonly originated form the nerve roots, the variants involved in NB imitation and progression remain to be elucidated. The outcome of low to intermediate risk disease is favorable whereas the high risk NB disease with dismal prognosis, positing the necessity of novel approaches for early detection and prognostication of advanced disease. Tailored immunotherapy approaches have shown significant improvement in high‐risk NB patients. It has found a link between Gangliosides and progression of NB. The vast majority of neuroblastoma tumors express elevated levels of GD2, opening new insight into using anti‐GD2 drugs as potential treatments for NBs. Implication of anti‐GD2 monoclonal antibodies for treatment of high risk NBs triggers further investigation to unearth novel biomarkers as prognostic and response biomarker to guide additional multimodal tailored treatment approaches. A growing body of evidence supports the usefulness of miRNAs to evaluate high risk NBs response to anti‐GD2 drugs and further prevent drug‐related toxicities in refractory or recurrent NBs. miRNAs and circulating proteins in body fluids (plasma and serum) present as potential biomarkers in early detection of NBs. Here, we summarize various biomarkers involved in diagnosis, prognosis and response to treatment in patients with NB. We further attempted to overview prognostic biomarkers in response to treatment with anti‐GD2 drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jcp.25793

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 105

Metadata

Authors
Gholamin, S., Mirzaei, H., Razavi, S., Hassanian, S. M., Saadatpour, L., Masoudifar, A., ShahidSales, S., & Avan, A.
Venue
Journal of Cellular Physiology
Publisher
Wiley
Published
2017-05-23
Volume
233
Issue
2
Pages
866-879
ISSN
  • 0021-9541 (ISSN-L)
  • 1097-4652
OpenAlex
W2592579739
Cited by
105
References
4
FWCI
13.83
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GD2‐targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma. https://app.cochat.ai/papers/10.1002/jcp.25793
The paper
Gholamin, S., Mirzaei, H., Razavi, S., Hassanian, S. M., Saadatpour, L., Masoudifar, A., ShahidSales, S., & Avan, A. (2018). GD2‐targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.25793

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.